enzalutamide

You have access
Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience
LI-WEN CHANG, SHENG-CHUN HUNG, SHIAN-SHIANG WANG, JIAN-RI LI, CHENG-KUANG YANG, CHUAN-SHU CHEN, HAO-CHUNG HO, CHEN-LI CHENG, YEN-CHUAN OU and KUN-YUAN CHIU

Anticancer Research July 2019, 39 (7) 3901-3908; DOI: https://doi.org/10.21873/anticanres.13541
You have access
Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression
DANIEL J. BECKER, ARJUN D. IYENGAR, SALMAN R. PUNEKAR, JASON NG, ANIKA ZAMAN, STACY LOEB, KEVIN D. BECKER and DANIL MAKAROV

Anticancer Research May 2019, 39 (5) 2467-2473; DOI: https://doi.org/10.21873/anticanres.13366
You have access
Quantification of Bone Metastasis of Castration-resistant Prostate Cancer After Enzalutamide and Abiraterone Acetate Using Bone Scan Index on Bone Scintigraphy
SUGURU KADOMOTO, HIROSHI YAEGASHI, KAZUFUMI NAKASHIMA, MASASHI IIJIMA, SHOHEI KAWAGUCHI, TAKAHIRO NOHARA, KAZUYOSHI SHIGEHARA, KOUJI IZUMI, YOSHIFUMI KADONO, KENICHI NAKAJIMA and ATSUSHI MIZOKAMI

Anticancer Research May 2019, 39 (5) 2553-2559; DOI: https://doi.org/10.21873/anticanres.13377
You have access
Age Adjusted Charlson Comorbidity Index Strongly Influences Survival, Irrespective of Performance Status and Age, in Patients With Advanced Prostatic Cancer Treated With Enzalutamide
HENDRIK KAREL VAN HALTEREN and GERARD VREUGDENHIL

Anticancer Research February 2019, 39 (2) 863-866; DOI: https://doi.org/10.21873/anticanres.13186
You have access
Exploring the Role of Enzalutamide in Combination with Radiation Therapy: An In Vitro Study
LUCA TRIGGIANI, ANTONELLA COLOSINI, MICHELA BUGLIONE, NADIA PASINETTI, FLAVIA ORIZIO, LILIA BARDOSCIA, PAOLO BORGHETTI, MARTA MADDALO, LUIGI SPIAZZI, STEFANO MARIA MAGRINI and ROBERTO BRESCIANI

Anticancer Research June 2018, 38 (6) 3487-3492; DOI: https://doi.org/10.21873/anticanres.12619
You have access
Mifepristone Has Limited Activity to Enhance the In Vivo Efficacy of Docetaxel and Enzalutamide Against Bone Metastatic and Castration-Resistant Prostate Cancer
YANG YANG, XIN LI, KENZA MAMOUNI, OMER KUCUK and DAQING WU

Anticancer Research November 2017, 37 (11) 6235-6243;
You have access
PCA3 Silencing Sensitizes Prostate Cancer Cells to Enzalutamide-mediated Androgen Receptor Blockade
EMRE ÖZGÜR, AYCA IRIBAS CELIK, EMIN DARENDELILER and UGUR GEZER

Anticancer Research July 2017, 37 (7) 3631-3637;
You have access
The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study
GIUSEPPE CICERO, ROSSELLA DE LUCA, PATRIZIA DORANGRICCHIA and FRANCESCO DIELI

Anticancer Research March 2017, 37 (3) 1475-1480;
You have access
Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer
HARUO KATO, YOSUKE FURUYA, YOSHIYUKI MIYAZAWA, TAKESHI MIYAO, TAKAHIRO SYUTO, MASASHI NOMURA, YOSHITAKA SEKINE, HIDEKAZU KOIKE, HIROSHI MATSUI, YASUHIRO SHIBATA, KAZUTO ITO and KAZUHIRO SUZUKI

Anticancer Research November 2016, 36 (11) 6141-6149;
You have access
Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer
RHIAN SIÂN DAVIES, CHRISTIAN SMITH and JASON FRANCIS LESTER

Anticancer Research April 2016, 36 (4) 1799-1803;

Main menu

User menu

Search

enzalutamide

Pages